Caroline Piatek, MD
Hematology · Los Angeles, CANPI 1366746661
Payments from drug & device makers
Across 531 payments — averaging $2575.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$787K
- Apellis Pharmaceuticals, Inc.$130K
- Incyte Corporation$52K
- Rigel Pharmaceuticals, Inc.$47K
- Sanofi US Services Inc.$40K
- Dova Pharmaceuticals$39K
- plus $273K from 17 others
Across 22 payments — averaging $6849.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rigel Pharmaceuticals, Inc.$101K
- AstraZeneca$49K
- Novartis$446
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 205 | $787,165 |
| Apellis Pharmaceuticals, Inc. | 65 | $129,631 |
| Incyte Corporation | 47 | $51,505 |
| Rigel Pharmaceuticals, Inc. | 29 | $47,129 |
| Sanofi US Services Inc. | 4 | $39,976 |
| Dova Pharmaceuticals | 23 | $38,568 |
| Sobi, Inc | 16 | $35,770 |
| Argenx US, Inc. | 29 | $35,009 |
| Sanofi | 27 | $34,740 |
| Novartis | 34 | $31,927 |
| Kedrion Biopharma, Inc. | 7 | $29,700 |
| Eli Lilly | 2 | $27,783 |
| Janssen Research & Development, LLC | 2 | $20,359 |
| Vertex | 1 | $18,355 |
| Agios Pharmaceuticals, Inc. | 18 | $13,483 |
| Janssen Scientific Affairs, LLC | 10 | $12,539 |
| Janssen Global Services, LLC | 3 | $6,540 |
| Recordati_rare_diseases_inc. | 2 | $3,130 |
| Samsung Bioepis Co., Ltd. | 2 | $2,170 |
| Regeneron | 1 | $1,662 |
| Bristol Myers Squibb | 2 | $163 |
| Beigene USA, Inc. | 1 | $125 |
| Servier Pharmaceuticals LLC | 1 | $22 |
How this compares
$1,367,453 in reported general payments places this provider in the 70th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Los Angeles
- Ilene WeitzLos Angeles$5.2M
- Doris QuonLos Angeles$2M
- Tait ShanafeltStanford$441.4M
- Alex HerreraDuarte$50.9M
- Hope RugoSan Francisco$23.8M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.